Richmond News Now

Choroideremia Pipeline Analysis: Insights into the Emerging Therapies, Clinical Trials, and Key Companies

 Breaking News
  • No posts were found

Choroideremia Pipeline Analysis: Insights into the Emerging Therapies, Clinical Trials, and Key Companies

October 11
13:58 2021
Choroideremia Pipeline Analysis: Insights into the Emerging Therapies, Clinical Trials, and Key Companies
Choroideremia Pipeline
DelveInsight’s Choroideremia pipeline report provides comprehensive insights into the Choroideremia market’s current clinical development scenario and growth prospects. The report provides a detailed description of the drug, including the drug’s mechanism of action, clinical studies, NDA approvals, and product development activities involving the technology.

DelveInsight’s Choroideremia pipeline report provides comprehensive insights into the Choroideremia market’s current clinical development scenario and growth prospects. The report provides a detailed description of the drug, including the drug’s mechanism of action, clinical studies, NDA approvals, and product development activities involving the technology.

Key Takeaways from the Choroideremia Pipeline Report

  • The Choroideremia pipeline comprises emerging therapies in the different clinical stages, including BIIB111, SPK-7001, 4D-110, Metformin, and others. 

  • Key companies working to improve the Choroideremia treatment landscape include NightstaRx Ltd, Spark Therapeutics, 4D Molecular Therapeutics, Curative Biotech, among others.

  • The Choroideremia pipeline therapies in the late stages of development include BIIB111 (NightstaRx Ltd), SPK-7001 (Spark Therapeutics), and others.

  • 4D-110 is being developed and investigated in the phase I Choroideremia clinical trials by 4D Molecular Therapeutics.

  • Metformin (Curative Biotech) is still in the early phase of development, i.e., preclinical stage for Choroideremia. 

Request for the sample to know more about the choroideremia pipeline @ Choroideremia Pipeline Therapies Analysis

Choroideremia Overview

Choroideremia is a rare genetic vision disorder that affects more men than women. It is an X-linked recessive condition that causes the choroid, retinal pigment epithelium (RPE), and photoreceptors to degrade gradually. Females are the majority of carriers and are mostly unaffected, though they may experience minor symptoms such as blurred vision later in life.

Choroideremia Symptoms 

The disease usually manifests itself in childhood, around the age of five or six. The child develops night blindness, or the inability to see objects in dim lighting, followed by loss of peripheral vision due to choroid blood vessel degeneration. Loss of color vision as a result of macula degeneration is another common symptom.

Choroideremia Treatment

Choroideremia currently has no treatment or cure. However, depending on the intensity of the symptoms, the patient may be offered symptom-specific treatment. However, because Choroideremia is a genetic condition, gene therapy and small molecule medications may be viable treatment choices for Choroideremia patients.

Choroideremia Pipeline Analysis: Drug Profiles

BIIB111: NightstaRx Ltd

Product Description

NightstaRx Ltd developed BIIB111 for the treatment of Choroideremia. BIIB111 is a gene therapy treatment consisting of an AAV2 vector with recombinant human DNA meant to deliver REP1 protein to the retina.

Phase III

NCT03496012: NightstaRx Ltd. began a Phase III trial of retinal gene therapy for Choroideremia using an Adeno-Associated Viral Vector (AAV2) Encoding Rab Escort Protein 1 (REP1) in December 2017.

Choroideremia Pipeline Therapies and Key Companies 

  • BIIB111: NightstaRx Ltd

  • SPK-7001: Spark Therapeutics

  • 4D-110: 4D Molecular Therapeutics

  • Metformin: Curative Biotech

Find out more about the emerging drugs @ Choroideremia Emerging Therapies and Companies

Choroideremia Therapeutics Assessment

  • By Product Type

    • Monotherapy

    • Combination Therapy

  • By Stage

    • Discovery

    • Pre-Clinical

    • Phase I

    • Phase II

    • Phase III

    • Pre-registration

  • By Route of Administration

    • Inhalation

    • Intravenous

    • Oral

    • Subcutaneous

  • By Molecule Type

    • Small Molecule

    • Stem Cell Therapy

    • Gene Therapy

  • Targets

    • Immune System

    • Multiple Kinase

  • By Mechanism of Action

    • Protease Inhibitors

    • Immunomodulatory

Scope of the Report

Coverage: Global

Choroideremia Key Players: NightstaRx Ltd, Spark Therapeutics, 4D Molecular Therapeutics, Curative Biotech, among others

Choroideremia Pipeline Therapies: BIIB111, SPK-7001, 4D-110, Metformin, and others

Table of Contents 

1.

Introduction

2.

Executive Summary

3.

Choroideremia: Overview

4.

Choroideremia Analytical Perspective In-depth Commercial Assessment

5.

Choroideremia Pipeline Therapeutics

6.

Choroideremia Late Stage Products (Phase III)

7.

Choroideremia Mid Stage Products (Phase  II)

8.

Choroideremia Early Stage Products (Phase I & I/II)

9.

Choroideremia Preclinical Products

10.

Choroideremia Therapeutic Assessment

11.

Choroideremia Inactive Products

12.

Choroideremia Company-University Collaborations (Licensing/Partnering) Analysis

13.

Choroideremia Key Companies

14.

Choroideremia Key Products

15.

Choroideremia Unmet Needs

16.

Choroideremia Market Drivers and Barriers

17.

Choroideremia Future Perspectives and Conclusion

18.

Choroideremia Analyst Views

19.

Appendix

20.

About DelveInsight

For rich insights into Healthcare and Pharmaceutical News, visit Pharma, Healthcare, and Biotech Blog Posts

Key questions answered in the Choroideremia Pipeline Report

  • What are the therapy options for Choroideremia?

  • How many pharmaceutical companies are working on therapies for Choroideremia?

  • Which of these firms’ medications are the most popular?

  • What is the total number of Choroideremia drugs produced by each company?

  • How many Choroideremia medicines are currently in the early, mid, or late stages of development?

  • How many of the therapies now in development can be used alone or in conjunction with others?

  • What are the most crucial industry-industry and industry-academy cooperation, mergers and acquisitions, and licensing strategies that impact Choroideremia?

Related Reports

Choroidal Neovascularization Pipeline Insights

“Choroidal Neovascularization Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Choroidal Neovascularization market.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Sandeep Joshi
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: www.delveinsight.com/